AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 87 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $111 | +56.3% | 245,678 | 0.0% | 0.04% | +59.3% |
| Q1 2023 | $71 | -36.0% | 245,678 | 0.0% | 0.03% | -35.7% |
| Q4 2022 | $111 | -99.9% | 245,678 | 0.0% | 0.04% | -12.5% |
| Q3 2022 | $129,000 | +4.0% | 245,678 | 0.0% | 0.05% | -11.1% |
| Q2 2022 | $124,000 | -78.1% | 245,678 | 0.0% | 0.05% | -81.4% |
| Q1 2022 | $565,000 | -51.6% | 245,678 | 0.0% | 0.29% | -45.1% |
| Q4 2021 | $1,167,000 | -40.2% | 245,678 | 0.0% | 0.53% | -52.5% |
| Q3 2021 | $1,953,000 | +4.1% | 245,678 | -8.9% | 1.12% | -22.4% |
| Q2 2021 | $1,876,000 | -15.3% | 269,578 | -3.6% | 1.44% | +10.7% |
| Q1 2021 | $2,215,000 | +0.6% | 279,678 | 0.0% | 1.30% | -45.4% |
| Q4 2020 | $2,201,000 | +11.0% | 279,678 | 0.0% | 2.38% | +15.5% |
| Q3 2020 | $1,983,000 | -23.3% | 279,678 | 0.0% | 2.06% | -79.4% |
| Q2 2020 | $2,587,000 | +72.0% | 279,678 | -13.3% | 10.00% | +382.1% |
| Q1 2020 | $1,504,000 | -39.0% | 322,658 | 0.0% | 2.08% | -21.2% |
| Q4 2019 | $2,465,000 | +7.3% | 322,658 | -3.8% | 2.63% | -7.4% |
| Q2 2019 | $2,297,000 | -14.9% | 335,279 | 0.0% | 2.84% | -17.2% |
| Q1 2019 | $2,699,000 | +7.5% | 335,279 | 0.0% | 3.43% | +26.6% |
| Q4 2018 | $2,511,000 | -21.8% | 335,279 | 0.0% | 2.71% | -31.6% |
| Q3 2018 | $3,209,000 | -11.0% | 335,279 | -1.6% | 3.97% | +185.7% |
| Q2 2018 | $3,604,000 | -30.8% | 340,679 | -35.1% | 1.39% | -32.4% |
| Q1 2018 | $5,207,000 | +83.3% | 524,929 | 0.0% | 2.05% | -81.3% |
| Q4 2017 | $2,840,000 | +9.7% | 524,929 | 0.0% | 10.96% | +76.9% |
| Q3 2017 | $2,588,000 | +28.1% | 524,929 | 0.0% | 6.20% | +3.2% |
| Q2 2017 | $2,021,000 | -48.3% | 524,929 | 0.0% | 6.01% | -41.2% |
| Q1 2017 | $3,911,000 | +71.3% | 524,929 | 0.0% | 10.21% | +56.0% |
| Q4 2016 | $2,283,000 | -32.2% | 524,929 | 0.0% | 6.55% | -27.0% |
| Q3 2016 | $3,365,000 | – | 524,929 | – | 8.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |